In Vivo Interaction Study
CsA in Renal Transplant patients
Increased systemic exposure was detected.
Fluctuation Index: Control - 2.8 (0.6) Test 1.4 (0.7) p<0.01
|Sample||Compound measured||Measurement||Value||Study sequence||Additional information||N replicates|
Within 1 month after receiving the renal transplant operation, six recipients (three males and three females) were selected—44.0±4.5 years in age, 165.2±8.8 cm in height and 59.0±13.9 kg in weight. All had normal hepatic function. They had been treated orally with 3 mg/kg CsA (twice per day) for 12.7±5.9 days before the start of the trial.
0, 2, 4, 6, 8,10, 12 hours
Drug or Natural Product Administration
three times daily
Pharmacodynamics (PD) & Adverse Events